New class includes a diverse range of expertise including biophysics, cardiology, ophthalmology, bioengineering, cancer biology, and more
Please join us in welcoming our newest 2023 Class of AV Fellows. Selected from more than 400 applications, the 2023 class includes 14 leading PhD, MD, and postdoc candidates from world-renowned institutions globally, with a diverse range of backgrounds including biophysics, cardiology, ophthalmology, bioengineering, cancer biology, and more. The class will work closely with the our team to support all aspects of the investment process, from due diligence and deal sourcing to portfolio support.
The year-long program is an opportunity for students currently enrolled in a PhD or MD program (or postdoc/residency) to gain real-world experience by working directly with impactful healthcare startups from the ARTIS Ventures portfolio, learn about new cutting-edge TechBio technologies, and collaborate with other fellows and alumni as well as the broader AV Healthcare Pioneers network, an ecosystem of pharma and biotech execs, investors, regulators, LPs, and more.
“We launched our Fellows Program in 2021 and each year have seen a significant increase in applications and calibur from brilliant, qualified candidates,” said Vasudev Bailey, PhD, Managing Partner at ARTIS Ventures. “This new group includes 14 of the brightest up-and-coming minds in science and health, and we are confident they will have a tremendous impact for ARTIS and our portfolio companies.”
Meet the 2023 AV Fellows
Founded in 2001, ARTIS Ventures partners with entrepreneurs who are driven to positively impact their world through disruptive technological and scientific innovation, focusing on the intersection of computer science and life science, a convergence ARTIS calls TechBio.
For more information about the ARTIS Ventures Fellows Program or to sign-up for future information about upcoming programs and applications visit https://www.av.co/fellows. For more information about ARTIS Ventures, its team, and its portfolio, visit https://www.av.co.
About ARTIS Ventures
ARTIS Ventures (AV) partners with entrepreneurs who are driven to impact the world by reshaping and reinventing industries. The team supports its portfolio companies through their entire life cycle, from initial venture investment to public offering and beyond. As an early leader in the emerging TechBio® sector, ARTIS Ventures funds companies at the intersection of computer science and life science, applying engineering principles and data-enabled discovery to healthcare. Notable companies the firm has backed include Stemcentrx (acquired by Abbvie), Outpace Bio, Tessera Therapeutics, Freenome, Eko, Delix Therapeutics, Modern Meadow, Excision BioTherapeutics, Lemonaid Health (acquired by 23andMe), and more. For more information, visit www.av.co or email email@example.com.